The analysis of the long-term outcomes of sorafenib therapy in routine practice in imatinib and sunitinib resistant gastrointestinal stromal tumors (GIST)*

Piotr Rutkowski; Beata Jagielska; Jolanta Andrzejuk; Elzbieta Bylina; Iwona Lugowska; Tomasz Switaj; Hanna Kosela-Paterczyk; Katarzyna Kozak; Slawomir Falkowski; Anna Klimczak

doi:10.5114/wo.2017.72393

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

4/2017
vol. 21

Send email

Copy url:

abstract:

Original paper

The analysis of the long-term outcomes of sorafenib therapy in routine practice in imatinib and sunitinib resistant gastrointestinal stromal tumors (GIST)*

Piotr Rutkowski

,

Beata Jagielska

,

Jolanta Andrzejuk

,

Elzbieta Bylina

,

Iwona Lugowska

,

Tomasz Switaj

,

Hanna Kosela-Paterczyk

,

Katarzyna Kozak

,

Slawomir Falkowski

,

Anna Klimczak

Contemp Oncol (Pozn) 2017; 21 (4): 285-289

DOI: https://doi.org/10.5114/wo.2017.72393

Online publish date: 2017/12/30

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Rutkowski P, Jagielska B, Andrzejuk J, et al. The analysis of the long-term outcomes of sorafenib therapy in routine practice in imatinib and sunitinib resistant gastrointestinal stromal tumors (GIST)*. Contemporary Oncology/Współczesna Onkologia. 2017;21(4):285-289. doi:10.5114/wo.2017.72393.

APA

Rutkowski, P., Jagielska, B., Andrzejuk, J., Bylina, E., Lugowska, I.,  & Switaj, T. et al. (2017). The analysis of the long-term outcomes of sorafenib therapy in routine practice in imatinib and sunitinib resistant gastrointestinal stromal tumors (GIST)*. Contemporary Oncology/Współczesna Onkologia, 21(4), 285-289. https://doi.org/10.5114/wo.2017.72393

Chicago

Rutkowski, Piotr, Beata Jagielska, Jolanta Andrzejuk, Elzbieta Bylina, Iwona Lugowska, Tomasz Switaj,  and Hanna Kosela-Paterczyk et al. 2017. "The analysis of the long-term outcomes of sorafenib therapy in routine practice in imatinib and sunitinib resistant gastrointestinal stromal tumors (GIST)*". Contemporary Oncology/Współczesna Onkologia 21 (4): 285-289. doi:10.5114/wo.2017.72393.

Harvard

Rutkowski, P., Jagielska, B., Andrzejuk, J., Bylina, E., Lugowska, I., Switaj, T., Kosela-Paterczyk, H., Kozak, K., Falkowski, S.,  and Klimczak, A. (2017). The analysis of the long-term outcomes of sorafenib therapy in routine practice in imatinib and sunitinib resistant gastrointestinal stromal tumors (GIST)*. Contemporary Oncology/Współczesna Onkologia, 21(4), pp.285-289. https://doi.org/10.5114/wo.2017.72393

MLA

Rutkowski, Piotr et al. "The analysis of the long-term outcomes of sorafenib therapy in routine practice in imatinib and sunitinib resistant gastrointestinal stromal tumors (GIST)*." Contemporary Oncology/Współczesna Onkologia, vol. 21, no. 4, 2017, pp. 285-289. doi:10.5114/wo.2017.72393.

Vancouver

Rutkowski P, Jagielska B, Andrzejuk J, Bylina E, Lugowska I, Switaj T et al. The analysis of the long-term outcomes of sorafenib therapy in routine practice in imatinib and sunitinib resistant gastrointestinal stromal tumors (GIST)*. Contemporary Oncology/Współczesna Onkologia. 2017;21(4):285-289. doi:10.5114/wo.2017.72393.

PlumX metrics:

Aim of the study was to analyze the outcome of treatment and factors predicting results of sorafenib therapy in inoperable/metastatic CD117-positive GIST patients after failure on imatinib and sunitinib.

Material and methods: We identified 60 consecutive patients (40 men, 20 women) with advanced inoperable/metastatic GIST after failure on at least imatinib and sunitinib treated in one sarcoma center with sorafenib at initial dose 2 × 400 mg daily in 2007–2015 (in 56 cases it was 3rd line therapy). Median follow-up time was 39 months.

Results: One year progression-free survival (PFS; calculated from the date of the start of sorafenib to disease progression) rate was 23% and median PFS = 7.7 months. The median overall survival (OS) was 13.5 months calculated from sorafenib start (1-year OS rate = 57%) and 7 years from imatinib start. Three patients (5%) had objective partial responses to therapy, 31 patients (52%) had stabilization of disease > 4 months. Primary tumor mutational status was known in 43 cases (73%), but we have not identified the differences in PFS between tumors carrying different KIT/PDGFRA mutations. The most common adverse events were: diarrhoea, hand and foot syndrome, fatigue, loss of weight and skin reactions; grade 3–5 toxicity occurred in 35% of patients. 23 patients required sorafenib dose reductions due to AEs.

Conclusions: We confirmed that many advanced GIST patients benefit from sorafenib therapy after imatinib/sunitinib failure with OS > 1 year.

keywords:

The analysis of the long-term outcomes of sorafenib therapy in routine practice in imatinib and sunitinib resistant gastrointestinal stromal tumors (GIST)*

Piotr Rutkowski , Beata Jagielska , Jolanta Andrzejuk , Elzbieta Bylina , Iwona Lugowska , Tomasz Switaj , Hanna Kosela-Paterczyk , Katarzyna Kozak , Slawomir Falkowski , Anna Klimczak

gastrointestinal stromal tumor, sorafenib, metastases, therapy

Piotr Rutkowski

,

Beata Jagielska

,

Jolanta Andrzejuk

,

Elzbieta Bylina

,

Iwona Lugowska

,

Tomasz Switaj

,

Hanna Kosela-Paterczyk

,

Katarzyna Kozak

,

Slawomir Falkowski

,

Anna Klimczak